A Phase 1 interventional study of MK-4074 200 mg and Placebo for MK-4074 in Non-alcoholic Fatty Liver Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-09-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 4 under way, none of them phase 3. Pioglitazone · Non-alcoholic Fatty Liver Disease.
Among the 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease, this one is the 15th largest by enrollment, is the only one that started in 2011, is the only one in phase 1, and was the 8th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →4 of the 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
University of Florida · Sites in United States
Ages 21–75
Badr University · Sites in Egypt
Ages 18–65
Jinnah Postgraduate Medical Centre · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 96 across the 19 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2011, is one of 3 in phase 1, and was the 2nd registered.
Merck & Co., Inc’s Non-alcoholic Fatty Liver Disease studies by the year they started, since 2010.
2 of the studies testing pioglitazone in Non-alcoholic Fatty Liver Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing pioglitazone in Non-alcoholic Fatty Liver Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 11 in Non-alcoholic Fatty Liver Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease. The primary hypothesis of the study is that a multiple-dose administration of MK-4074 200 mg twice daily for 4 weeks results in a decrease in hepatic fat content with respect to placebo in adult male and female participants with hepatic steatosis (i.e., on order of 50% reduction in hepatic fat with respect to placebo is expected).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
Drug: MK-4074 200 mg
Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
Drug: Placebo for MK-4074
Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
Drug: Pioglitazone hydrochloride 30 mg
Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
Drug: Placebo for pioglitazone hydrochloride
2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
2 x 100-mg capsules, orally, BID for 4 weeks.
1 x 30-mg tablet, orally, once daily for 4 weeks
1 x 30-mg tablet, orally, once daily for 4 weeks
Percent Change From Baseline in Hepatic Fat
Hepatic fat content was assessed via magnetic resonance imaging (MRI) prior to first dose administration and following 4 weeks of treatment. Percent change in hepatic fat fraction from baseline was calculated for each of the 9 liver regions separately and then these were averaged to calculate overall percent change from baseline for each participant.
Time frame: Baseline and Week 4
Number of Participants Experiencing One or More Adverse Events (AE)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 10 weeks
Number of Participants Who Discontinued Study Drug Due to an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 4 weeks
Percent Change From Baseline in Alanine Transaminase (ALT)
Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, specifically ALT, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.
Time frame: Baseline and Week 4
Percent Change From Baseline Aspartate Transaminase (AST)
Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, including AST, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.
Time frame: Baseline and Week 4
Thirty-one male or female participants (non-childbearing potential) between the ages of 18 and 60, inclusive, with body mass index (BMI) ≥ 32 kg/m\^2 were enrolled in the study. Participants were pre-screened by means of ultrasound, and only those participants with a rating of "moderate" or "severe" steatosis were further evaluated by means of MRI.
| Milestone | MK-4074 | Placebo for MK-4074 | Pioglitazone | Placebo for Pioglitazone |
|---|---|---|---|---|
| Started | 10 | 5 | 11 | 5 |
| Treated | 10 | 5 | 10 | 5 |
| Completed | 10 | 5 | 10 | 5 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Hepatic fat content was assessed via magnetic resonance imaging (MRI) prior to first dose administration and following 4 weeks of treatment. Percent change in hepatic fat fraction from baseline was calculated for each of the 9 liver regions separately and then these were averaged to calculate overall percent change from baseline for each participant.
| Percent change | MK-4074 | Pioglitazone | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Hepatic Fat | -35.73 (-44.53 to -26.93) | -18.04 (-26.84 to -9.24) | 8.63 (-0.17 to 17.43) |
Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, specifically ALT, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.
| Percent change | MK-4074 | Pioglitazone | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Alanine Transaminase (ALT) | -9.82 (-21.13 to 1.49) | -20.21 (-31.52 to -8.90) | -3.47 (-15.08 to 8.13) |
Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, including AST, and these elevations may be a marker of more advanced hepatic disease. Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.
| Percent change | MK-4074 | Pioglitazone | Placebo |
|---|---|---|---|
| Percent Change From Baseline Aspartate Transaminase (AST) | -6.74 (-19.73 to 6.24) | -13.95 (-26.93 to -0.97) | -3.28 (-16.64 to 10.08) |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Participants | MK-4074 | Pioglitazone | Placebo |
|---|---|---|---|
| Number of Participants Experiencing One or More Adverse Events (AE) | 4 | 4 | 5 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Participants | MK-4074 | Pioglitazone | Placebo |
|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an AE | 0 | 0 | 0 |
Collected over Up to 10 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-4074 | — | 0/10 (0%) | 4/10 (40%) |
| Placebo for MK-4074 | — | 0/5 (0%) | 1/5 (20%) |
| Pioglitazone | — | 0/10 (0%) | 4/10 (40%) |
| Placebo for Pioglitazone | — | 0/5 (0%) | 4/5 (80%) |
| Event | MK-4074 | Placebo for MK-4074 | Pioglitazone | Placebo for Pioglitazone |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/10 | 0/5 | 0/10 | 1/5 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/10 | 0/5 | 0/10 | 1/5 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 1/5 | 1/10 | 0/5 |
| DizzinessNervous system disorders | 0/10 | 0/5 | 1/10 | 1/5 |
| HeadacheNervous system disorders | 1/10 | 0/5 | 2/10 | 1/5 |
| MigraineNervous system disorders | 0/10 | 1/5 | 0/10 | 0/5 |
| AnxietyPsychiatric disorders | 0/10 | 0/5 | 0/10 | 1/5 |
| PruritusSkin and subcutaneous tissue disorders | 0/10 | 1/5 | 0/10 | 0/5 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/10 | 0/5 | 0/10 | 1/5 |
| Eyelids pruritusEye disorders | 0/10 | 0/5 | 0/10 | 1/5 |
| Age, Continuous(Years) | MK-4074 | Placebo for MK-4074 | Pioglitazone | Placebo for Pioglitazone | Total |
|---|---|---|---|---|---|
| Mean | 35.1 ± 5.8 | 48.0 ± 7.6 | 43.7 ± 12.1 | 47.8 ± 10.6 | 42.3 ± 10.5 |
| Sex: Female, Male(Participants) | MK-4074 | Placebo for MK-4074 | Pioglitazone | Placebo for Pioglitazone | Total |
|---|---|---|---|---|---|
| Female | 0 | 1 | 2 | 4 | 7 |
| Male | 10 | 4 | 9 | 1 | 24 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Oct 2011 to primary completion in Sep 2012, 10 months.
Results were first posted in Mar 2016, 3 years 6 months after primary completion.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 10 months is close to that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone
Non-alcoholic Fatty Liver Disease →